Search results
Showing 991 to 1005 of 1559 results for do not do recommendations
type of surgery you are thinking of choosing. You might also decide that you do not want to try any of these options just yet, and see...
Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma (HTG394)
Evidence-based recommendations on radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma. This involves using pulses of radiofrequency heat energy to damage the nerve, with the aim of reducing pain.
View recommendations for HTG394Show all sections
Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.
View recommendations for HTG41Show all sections
Sections for HTG41
Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (HTG652)
Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.
View recommendations for HTG652Show all sections
Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults.
Evidence-based recommendations on AposHealth for knee osteoarthritis.
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia with more than 30% bone marrow blasts.
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Help us improve NICE: take part in research to help us develop better products and services.
Help us improve NICE: take part in research to help us develop better products and services.